Key result
Mechanical heart valve replacement in a sub-Saharan center resulted in 93.1% freedom from neurologic events and 78.9% freedom from anticoagulation-related bleeding at 6 years.
Cohort (n=233)
No
Mechanical heart valve replacement in a resource-limited sub-Saharan setting demonstrates acceptable midterm outcomes with high freedom from neurologic events and no valve thrombosis, though anticoagulation-related bleeding remains a risk.
Supports mechanical valve use in sub-Saharan centers with monitoring; leaves open need for RCTs to confirm long-term safety.
BACKGROUND: The management of patients with mechanical heart valves remains a major concern in populations with limited resources and medical facilities. This study reports the clinical outcomes of patients who underwent mechanical valve implantation in a sub-Saharan center over an 8-year period. METHODS: A total of 291 mechanical valves were implanted in 233 patients in our institution between February 2008 and June 2016. A total of 117 patients underwent mitral valve replacement (MVR, 50.2%), 57 had aortic valve replacement (AVR, 24.4%), and 59 underwent both AVR and MVR (double valve replacement [DVR], 25.7%). The mean age at surgery was 27.6 ± 13.4 years (range, 7-62 years). Rheumatic etiology was found in 80.6% of the patients. Hospital mortality, late deaths, and valve-related events were reviewed at follow-up (839 patient-years, range: 1-9.4 years, complete in 93%). RESULTS: = 0.15). The freedom from neurologic events and anticoagulation-related bleeding at 6 years was 93.1 ± 2.1% and 78.9 ± 3.7%, respectively. No patient had reoperation at follow-up. No case of prosthetic valve thrombosis was identified. Eight full-term pregnancies were reported. CONCLUSION: This preliminary experience reports acceptable midterm results after mechanical heart valve implantation in our region. Both accurate surgical evaluation and strategies, either financial or social, facilitating patient's education and medical assistance are crucial to ensure good results. Long-term follow-up and further studies comparing current nonthrombogenic options are warranted to draw reliable conclusions.
No takes yet. Share an insight, caveat, or question.
Mvondo et al. (2018) conducted a cohort in Valvular heart disease requiring replacement (predominantly rheumatic) (n=233). Mechanical heart valve replacement was evaluated on Freedom from neurologic events and anticoagulation-related bleeding at 6 years. Mechanical heart valve replacement in a sub-Saharan center resulted in 93.1% freedom from neurologic events and 78.9% freedom from anticoagulation-related bleeding at 6 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: